Introduction {#sec0005}
============

Influenza is an acute respiratory illness that causes local outbreaks and seasonal epidemics worldwide ([@bib0060]). Globally, the disease burden of influenza-associated respiratory mortality is as high as 290,000--650,000 annual deaths ([@bib0035]). Approximately 15--45% of children are known to be infected with influenza during a given season. High viremic titers and long periods of viral shedding in children represent a critical source in the transmission of influenza in the community ([@bib0055], [@bib0060]). The influenza vaccine is the most effective public health measure for preventing influenza.

The performance of the vaccine could be evaluated by estimating the vaccine effectiveness (VE) ([@bib0110], [@bib0085], [@bib0090], [@bib0070]). A previous study on VE of live attenuated influenza vaccines showed less effectiveness that led to alteration in the recommendation of this vaccine ([@bib0015]). The VE appears to have a wide range by age group, regional difference, and season. This discrepancy in VE may be attributable to various factors, such as vaccine coverage rate, season, manufacturing of vaccines, host factor and investigational bias ([@bib0050]). In children aged 5 years and younger, this variability may increase to 15--85% ([@bib0080], [@bib0010], [@bib0095]).

Seasonal influenza generally occurs from November to April of the following year in Korea. In the 2017--2018 season, the Korean National Immunization Program for influenza is recommended for people who are at a high risk for developing complications from influenza. Since the 2017--2018 influenza season, Korea Centers for Disease Control and Prevention has provided free inactivated trivalent influenza vaccines (IIV3) for all children aged 6--59 months. In this study, we aimed to estimate the VE of IIV3 in preventing laboratory-confirmed influenza in children during the 2017--2018 influenza season when lineage-mismatched influenza B virus circulated. In addition, we compared the VE based on the rapid influenza diagnostic test (RIDT) or reverse transcription polymerase chain reaction (RT-PCR) test results.

Methods {#sec0010}
=======

Study design {#sec0015}
------------

This study setting included Seoul National University Children\'s Hospital (Seoul), Seoul National University Bundang Hospital (Seongnam), Chungbuk National University Hospital (Cheongju), and Jeju National University Hospital (Jeju). We enrolled children from 6 months to 59 months old who visited the four hospitals for influenza-like illness from November 2017 to April 2018. Children were excluded if they had an immunodeficiency disorder, received long-term use of high-dose steroids, or received quadrivalent inactivated influenza vaccines (IIV4). Only the first episode was included when more than one test was positive for the same influenza subtype. Vaccination within 2 weeks was not considered valid. Clinical information was collected from retrospective medical records and vaccination status (date of vaccination, vaccine type, and number of vaccinations) was confirmed from the National Immunization Registry Information System.

A rapid influenza diagnostic test (RIDT) and reverse transcription polymerase chain reaction (RT-PCR) were used for the diagnosis of influenza. Both tests were done when the patient presented the influenza like illness. RIDTs were mainly used to identify the influenza rapidly in the emergency room, and most RT-PCRs were used to differentiate from other respiratory infections for inpatients. Nasopharyngeal specimens were collected either by the swab method using flocked swabs or aspiration. RIDT was performed with the Sofia influenza A+B FIA Kit (Quidel, San Diego, CA, USA), BD Veritor™ Plus system (BD Diagnostics, Sparks, MD, USA), or Standard F Influenza A/B FIA (SD Biosensor Inc., Suwon, Korea). RT-PCR was performed by the Allplex™ Respiratory Panel Assays (Seegene Inc., Seoul, Korea), One-Step RV Detection Kit (BioSewoom Inc., Seoul, Korea), or in-house method according to the manufacturer\'s instructions.

Data analysis {#sec0020}
-------------

VE against laboratory-confirmed influenza was estimated by using a test-negative case-control design. Cases were defined as children who were confirmed to have influenza by laboratory tests either by RIDT or by RT-PCR. Controls were children who were negative as per the influenza tests. The VE was calculated as: \[1 − odds ratio (OR) × 100\]%, and 95% confidence interval (CI) was calculated for each estimate.

The statistical analysis was performed using R software version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria). Logistic regression models were adjusted for age, and week of visit.

Results {#sec0025}
=======

Patient characteristics {#sec0030}
-----------------------

A total of 4738 children were enrolled in this study. Clinical characteristics of enrolled subjects according to participating hospitals are shown in [Table 1](#tbl0005){ref-type="table"} . In total, 2143 (45.2%) children were female and the median age was 19.6 months. The numbers of respiratory specimens collected by each hospital were 3837 (81.0%) at emergency units, followed by 572 (12.1%) at outpatient clinics and 517 (10.9%) at general wards. There were no fatal cases. The proportion vaccinated was 82.1% (3889/4738).Table 1Clinical characteristics, test for influenza, and influenza cases at four hospitals in Korea.Table 1CharacteristicHospital 1Hospital 2Hospital 3Hospital 4TotalTotal patients1173 (24.8)1138 (24.0)1133 (23.9)1294 (27.3)4738Gender, male: female635:538618:520642:491700:5942595:2143Median age, yr ± SD1.81 ± 1.201.80 ± 1.171.48 ± 1.081.54 ± 1.101.64 ± 1.14Hospital visitInpatient17910441193517Outpatient444539489572Emergency room107798969810123837Test for influenza (RIDT/RT-PCR)1115/222971/296761/3981164/2744012/1190Influenza cases261 (22.3)196 (17.2)126 (11.1)262 (20.2)845 (17.8)[^2][^3]

One thousand one hundred ninety patients were tested for influenza by RT-PCR, 4012 patients by RIDT, and 464 patients by both RT-PCR and RIDT ([Table 2](#tbl0010){ref-type="table"} ). Influenza was detected in 845 children (17.8%), leaving the other 3893 children (82.2%) to serve as controls. Sixty-two (7.3%) children were hospitalized. In detail, 478 (56.6%) had influenza A, 362 (42.8%) had influenza B, and 5 (0.6%) had influenza A and B. Eight hundred four patients were diagnosed with RIDT, 80 with RT-PCR and 57 with both tests.Table 2The prevalence of influenza according to diagnostic methods.Table 2No. (%) of testsRT-PCRRIDTBoth testsTested number of patients11904012464Any influenza87 (7.3)804[a](#tblfn0005){ref-type="table-fn"} (20.0)57[b](#tblfn0010){ref-type="table-fn"} (12.3)Influenza A3746925Influenza B5034032[^4][^5][^6]

Among the 845 children who were confirmed to have influenza, 669 (79.2%) were vaccinated during the corresponding season. Of the 3893 children who were negative for influenza, 3220 (82.7%) were vaccinated. Among vaccinated children, 17.2% had influenza compared to 20.7% among unvaccinated children.

Vaccine effectiveness using RT-PCR {#sec0035}
----------------------------------

Applying only the RT-PCR test, adjusted VE was 53.4% (95% CI, 25.3 to 70.5) against any influenza, 68.8% (95% CI, 38.7 to 84.1) against influenza A, and 29.7% (95% CI, −35.1 to 61.8) for influenza B. Among 464 patients who were tested by both RIDT and RT-PCR, adjusted VE against any influenza was 36.7% (95% CI, −20.2 to 65.8) using the RT-PCR method. In detail, adjusted VE was 58.7% (95% CI, 41.9 to 84.6) against influenza A, and 14.9% (95% CI, −100.6 to 61.0) against influenza B.

Comparison of vaccine effectiveness using RIDT to RT-PCR {#sec0040}
--------------------------------------------------------

Applying the RIDT, adjusted VE based on the RIDT test was 14.8% (95% CI, −4.4 to 30.0) against any influenza, 24.2% (95% CI, 3.1--40.2) against influenza A, and −5.1% (95% CI, −42.6 to 21.4) against influenza B. Comparison of VE between RIDT and RT-PCR was shown in [Figure 1](#fig0005){ref-type="fig"}. Among the patients who were tested by both tests, adjusted VE against any influenza was 15.6% (95% CI, −59.6 to 56.0) using RIDT. RIDT based VE was lower than RT-PCR based VE ( [Figure 2](#fig0010){ref-type="fig"}). In detail, adjusted VE based on RIDT was 50.5% (95% CI, −17.8 to 78.4) against influenza A, and −17.8% (95% CI, −229.7 to 51.5) against influenza B. Comparison of VE by each hospital is shown in [Table 3](#tbl0015){ref-type="table"} .Figure 1Adjusted vaccine effectiveness (VE) against influenza according to influenza type. (A) Influenza confirmed by real-time polymerase chain reaction (RT-PCR). (B) Influenza confirmed by rapid influenza diagnostic test (RIDT). Data are shown with dot (VE) and 95% confidence interval error bar.Figure 1Figure 2Adjusted vaccine effectiveness (VE) against influenza according to the testing method among the children who were tested by both real-time polymerase chain reaction (RT-PCR) and rapid influenza diagnostic test (RIDT). Data are shown with dot (VE) and 95% confidence interval error bar.Figure 2Table 3Comparison of vaccine effectiveness by hospitals.Table 3Hospital 1Hospital 2Hospital 3Hospital 4TotalVaccinated, *n* (%)934 (79.6)855 (75.1)1016 (89.7)1084 (83.8)3889 (82.1)*Vaccine effectiveness (VE)*Crude VE by RT-PCR(95% CI)78.3(43.2, 92.6)59.8(−48.0, 89.1)57.6(−5.6, 81.3)38.2(−66.0, 75.5)54.5(28.1, 70.8)Adjusted VE by RT-PCR[a](#tblfn0015){ref-type="table-fn"}\
(95% CI)74.3(31.4, 91.4)51.7(−86.8, 87.4)54.8(−15.7, 80.6)36.3(−77.5, 74.9)53.4(25.3, 70.5)Crude VE by RIDT(95% CI)2.1(−40.8, 30.9)12.3(−27.2, 38.8)13.8(−68.9, 52.9)26.7(4.3, 48.6)19.3(1.7--33.5)Adjusted VE by RIDT[a](#tblfn0015){ref-type="table-fn"}\
(95% CI)−8.8(−60.0, 24.9)−2.3(−51.0, 29.8)−6.0(−112.0, 43.4)25.3(0.0, 48.1)14.8(−4.4, 30.0)[^7][^8][^9]

Vaccine effectiveness according to age group {#sec0045}
--------------------------------------------

VE was subanalyzed after children were stratified into two age groups (6--35 months age: group 1, 36--59 months age: group 2). When using RT-PCR, VE against influenza was estimated as 44.1% (95% CI −0.2 to 67.8) in group 1 and 59.3% (95% CI, 8.8 to 81.9) in group 2 ([Figure 3](#fig0015){ref-type="fig"}A). VE using RIDT against influenza was estimated as 14.3% (95% CI, −10.9 to 33.3) in group 1 and −3.4% (95% CI, −41.4 to 23.9) in group 2 ( [Figure 3](#fig0015){ref-type="fig"}B).Figure 3Vaccine effectiveness (VE) against influenza according to age group. Group 1 was from 6 months to 2 years old and group 2 was from 3 to \<5 years old. (A) Influenza confirmed by real-time polymerase chain reaction (RT-PCR). (B) Influenza confirmed by rapid influenza diagnostic test (RIDT). Data are shown with dot (VE) and 95% confidence interval error bar.Figure 3

Discussion {#sec0050}
==========

In this study, we estimated the VE of IIV3 in children during the 2017--2018 influenza season when the mismatched influenza B strain circulated. The VE of the season estimated as 32--38% in Australia, Canada, and the US ([@bib0110], [@bib0085], [@bib0070]). However, VE was higher in children at 52% in Louisiana, US and 56% in Israel ([@bib0065], [@bib0075]). In the studies conducted in Asia, VE against influenza was estimated as 59% to 69% in Hong Kong and China ([@bib0020], [@bib0045]). However, in our study, VE varied according to the diagnostic testing method; adjusted VE based on RT-PCR was 53.4% (95% CI, 25.3--70.5) for any influenza, while adjusted VE using RIDT was 14.8% (95% CI, −4.4 to 30.0) for any influenza, suggesting the role of diagnostic sensitivity in affecting VE results. Given the similarity of the study design, the influenza vaccine in our study was similarly effective against influenza as in other studies.

In many countries, RT-PCR is regarded as the standard test for influenza when estimating the VE against all influenza due to the possible underestimation of VE from the low diagnostic sensitivity of RIDT ([@bib0030]). Previous reports indicate that the sensitivity and specificity of RIDT is comparable to that of RT-PCR, as in the cases in Japan ([@bib0115], [@bib0100], [@bib0105]). In our study, the sensitivity and specificity of RIDT using RT-PCR as gold standard were 73.7% and 97.6% among the patients who were tested by both tests. However, there was a substantial difference in the estimated VE between RT-PCR and RIDT. The ratio of controls to influenza cases was approximately 4:1. Lower estimates of VE by RIDT may be due to the fact that the test could detect influenza virus only for a narrower window period when the virus titer was sufficiently high. Children are also susceptible to various respiratory viruses other than influenza virus, for example, respiratory syncytial virus (RSV), rhinovirus, and coronavirus, which may cocirculate during the given influenza season. Attempts to test for influenza may have been made for children with other respiratory viruses. Although there was no difference in the age distribution between the RIDT and RT-PCR groups, indications for RIDT and RT-PCR were not identical in our study. Most RT-PCR tests were done in hospitalized patients as expected. In the subgroup analysis of the 464 patients who were examined by both tests, we demonstrated that VE using RT-PCR was higher than RIDT for all influenza as was shown in the separate analysis by each test method ([Figure 2](#fig0010){ref-type="fig"}). Although the ratio of using both tests was not significantly different among four hospitals, the difference of VEs by diagnostic methods in hospital 4 was small compared with other hospitals ([Table 3](#tbl0015){ref-type="table"}). Multifactorial factors may have contributed to the difference, such as unique epidemiology and pattern of seeking medical service related to the location of the Hospital 4 in Jeju Island. Further study is needed to explain the difference.

We also found difference in VE rates between virus subtypes. Using the RT-PCR test, the VE was 68.8% against influenza A and 29.7% against influenza B. In the 2017--2018 influenza season, the recommended vaccine constitution of trivalent vaccines consisted of an A/Michigan/45/2015(H1N1)pdm09-like virus, an A/Hong Kong/4801/2014(H3N2)-like virus, and a B/Brisbane/60/2008-like virus (Victoria lineage) ([@bib0120]). However, most influenza virus B circulated in the 2017-2018 season was influenza B/Yamagata lineage, resulting in vaccine-virus mismatch ([@bib0005], [@bib0090]). In the 2017--2018 season, influenza A (H3N2) accounted for approximately 80% of influenza A ([@bib0070]). According to the Korea Centers for Disease Control and Prevention laboratory sentinel surveillance system, influenza A and B were responsible for 44.6% and 55.4%, respectively, in the 2017--2018 influenza season ([@bib0040]). In Korea, this predominance of influenza B in the 2017--2018 influenza season was unusual compared to the previous influenza seasons. Moreover, influenza A (H3N2) was 86.8% of influenza A, suggesting that the influenza activity in Korea was similar with other countries in the Northern Hemisphere in the given season ([@bib0040]). Compared to influenza A, we found a limited VE of IIV3 against influenza B ([Figure 1](#fig0005){ref-type="fig"}). This lower VE can be explained by the influenza B mismatch between IIV3 and circulating strains. This lower VE against influenza B has been observed worldwide ([@bib0085], [@bib0020], [@bib0070]). In the age subgroup analysis, VE in the older age group was higher than that in the younger age group ([Figure 3](#fig0015){ref-type="fig"}). As children in the younger age group generally express symptoms inadequately, the criteria of influenza-like illness might have been broader and even children with RSV infection might have been included in this age group.

There are several limitations in this study. Given the retrospective design of the study, we were not able to apply uniform inclusion criteria for testing eligible children. Tests for influenza were made by clinical decision, resulting in possible ascertainment bias. We analyzed our data based on the crude numbers assuming that the clinical practices across all four hospitals were stable during the season. However, there may be detection bias since healthcare providers may not have thought of performing tests for influenza in certain periods or in a specific hospital. Furthermore, RIDT and RT-PCR test was not simultaneously examined, and so the comparison between two tests has limitations considering other prospective simultaneous study ([@bib0025]). Finally, our data were from four large hospitals, possibly limiting the generalizability of these results. A more diverse pool of children and easily accessible primary medical institution might give the generalizability to this study. Despite these limitations, this is the first study that assessed the VE of influenza vaccine in Korean children. We included the largest number of pediatric population pools from diverse areas in Korea. We used two different diagnostic methods (RIDT and RT-PCR) as the numerators of the study, providing additional information on assessing VE using different testing methods. Lastly, by applying the test-negative design, a modified case-control study, we aimed to minimize confounders, such as health care-seeking behavior, and reduce disease misclassification as an outcome measure.

In conclusion, we found a moderated effectiveness of IIV3 against influenza confirmed by RT-PCR in Korean children during the 2017--2018 season. Compared with RT-PCR, the substantial difference in estimated VE and known low sensitivity of RIDT showed that RIDT is an unsuitable assay for test-negative design of estimating VE. Given the limited effect of IIV3 against influenza B, discussion on including IIV4 in the Korean National Immunization Program should be in place. Continuous assessment of VE of influenza vaccine is needed to provide evidence required for making appropriate policies for the prevention of influenza.
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